Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study

BMC Medicine

María Isabel Queipo-Ortuño³  Federico Soriguer⁶  Fernando Cardona³  Francisco J Tinahones²  Juan Miguel Gomez-Zumaquero¹  Isabel Leiva⁴  Mora Murri⁵ 

[1]Molecular Biology Laboratory, Civil Hospital (IMABIS foundation), Plaza Hospital Civil s/n, Málaga, 29009, Spain

[2]Endocrinology and Nutrition Service, Virgen de la Victoria Hospital, Campus de Teatinos s/n, Málaga, 29010, Spain

[3]CIBER of Physiopathology of Obesity and Nutrition (CIBEROBN), Instituto de Salud Carlos III, C/ Sinesio Delgado nº 4, Madrid, 28029, Spain

[4]Pediatric Endocrinology Service, Carlos Haya Materno Infantil Hospital, Avenida Arroyo de los Angeles, Málaga, 29011, Spain

[5]Biomedical Research Laboratory, Virgen de la Victoria Hospital (FIMABIS), Campus de Teatinos s/n, Málaga, 29010, Spain

[6]CIBER of Diabetes and Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III, C/ Sinesio Delgado nº 4, Madrid, 28029, Spain

关键词: type 1 diabetes;    PCR-DGGE;    mucin;    mode of delivery;    lactic acid-producing bacteria;    HbA1c level;    gut permeability;    gut microbiota;    gut integrity;    glycemic level;    butyrate-producing bacteria;   

Others  :  857181
DOI  :  10.1186/1741-7015-11-46

 received in 2012-08-15, accepted in 2013-02-21,  发布年份 2013

【 摘 要 】

Background

A recent study using a rat model found significant differences at the time of diabetes onset in the bacterial communities responsible for type 1 diabetes modulation. We hypothesized that type 1 diabetes in humans could also be linked to a specific gut microbiota. Our aim was to quantify and evaluate the difference in the composition of gut microbiota between children with type 1 diabetes and healthy children and to determine the possible relationship of the gut microbiota of children with type 1 diabetes with the glycemic level.

Methods

A case-control study was carried out with 16 children with type 1 diabetes and 16 healthy children. The fecal bacteria composition was investigated by polymerase chain reaction-denaturing gradient gel electrophoresis and real-time quantitative polymerase chain reaction.

Results

The mean similarity index was 47.39% for the healthy children and 37.56% for the children with diabetes, whereas the intergroup similarity index was 26.69%. In the children with diabetes, the bacterial number of Actinobacteria and Firmicutes, and the Firmicutes to Bacteroidetes ratio were all significantly decreased, with the quantity of Bacteroidetes significantly increased with respect to healthy children. At the genus level, we found a significant increase in the number of Clostridium, Bacteroides and Veillonella and a significant decrease in the number of Lactobacillus, Bifidobacterium, Blautia coccoides/Eubacterium rectale group and Prevotella in the children with diabetes. We also found that the number of Bifidobacterium and Lactobacillus, and the Firmicutes to Bacteroidetes ratio correlated negatively and significantly with the plasma glucose level while the quantity of Clostridium correlated positively and significantly with the plasma glucose level in the diabetes group.

Conclusions

This is the first study showing that type 1 diabetes is associated with compositional changes in gut microbiota. The significant differences in the number of Bifidobacterium, Lactobacillus and Clostridium and in the Firmicutes to Bacteroidetes ratio observed between the two groups could be related to the glycemic level in the group with diabetes. Moreover, the quantity of bacteria essential to maintain gut integrity was significantly lower in the children with diabetes than the healthy children. These findings could be useful for developing strategies to control the development of type 1 diabetes by modifying the gut microbiota.

【 授权许可】

   
2013 Murri et al; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Marcovecchio ML, Tossavainen PH, Dunger DB: Prevention and treatment of microvascular disease in childhood type 1 diabetes. Br Med Bull 2010, 94:145-164.
• [2]Ehehalt S, Dietz K, Willasch AM, Neu A, Baden-Württemberg : Diabetes Incidence Registry (DIARY) Group. Epidemiological perspectives on type 1 diabetes in childhood and adolescence in Germany: 20 years of the Baden-Württemberg Diabetes Incidence Registry (DIARY). Diabetes Care 2010, 3:338-340.
• [3]Patterson CC, Dahlquist G, Soltesz G, Green A, Grp EAS: Is childhood onset Type I diabetes a wealth-related disease? An ecological analysis of European incidence rates. Diabetologia 2001, 4:9-16.
• [4]Vaarala O, Atkinson MA, Neu J: The ''perfect storm'' for type 1 diabetes - the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes 2008, 57:2555-2562.
• [5]Brugman S, Klatter FA, Visser JT, Wildeboer-Veloo AC, Harmsen HJ, Rozing J, Bos NA: Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat. Is the gut flora involved in the development of type 1 diabetes? Diabetologia 2006, 49:2105-2108.
• [6]Schwartz RF, Neu J, Schatz D, Atkinson MA, Wasserfall C: Comment on: Brugman S et al. (2006) Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat. Is the gut flora involved in the development of type 1 diabetes? Diabetologia 49:2105-2108. Diabetologia 2007, 50:220-221.
• [7]King C, Sarvetnick N: The incidence of type-1 diabetes in NOD mice is modulated by restricted flora not germ-free conditions. Plos One 2011, 6:e17049.
• [8]Roesch LFW, Lorca GL, Casella G, Giongo A, Naranjo A, Pionzio AM, Li N, Mai V, Wasserfall CH, Schatz D, Atkinson MA, Neu J, Triplett EW: Culture-independent identification of gut bacteria correlated with the onset of diabetes in a rat model. Isme J 2009, 3:536-548.
• [9]Lai KK, Lorca GL, Gonzalez CF: Biochemical properties of two cinnamoyl esterases purified from a Lactobacillus johnsonii strain isolated from stool samples of diabetes-resistant rats. Appl Environ Microbiol 2009, 75:5018-5024.
• [10]Valladares R, Sankar D, Li N, Williams E, Lai KK, Abdelgeliel AS, Gonzalez CF, Wasserfall CH, Larkin J, Schatz D, Atkinson MA, Triplett EW, Neu J, Lorca GL: Lactobacillus johnsonii N6.2 mitigates the development of type 1 diabetes in BB-DP rats. PLoS One 2010, 5:e10507.
• [11]Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, Hu C, Wong FS, Szot GL, Bluestone JA, Gordon JI, Chervonsky AV: Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 2008, 45:1109-1113.
• [12]Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, Wei D, Goldfarb KC, Santee CA, Lynch SV, Tanoue T, Imaoka A, Itoh K, Takeda K, Umesaki Y, Honda K, Littman DR: Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009, 139:485-498.
• [13]Ivanov II, Littman DR: Segmented filamentous bacteria take the stage. Mucosal Immunol 2010, 3:209-212.
• [14]Romano-Keeler J, Weitkamp JH, Moore DJ: Regulatory properties of the intestinal microbiome effecting the development and treatment of diabetes. Curr Opin Endocrinol Diabetes Obes 2012, 19:73-80.
• [15]Kuitunen M, Saukkonen T, Ilonen J, Akerblom HK, Savilahti E: Intestinal permeability to mannitol and lactulose in children with type 1 diabetes with the HLA-DQB1*02 allele. Autoimmunity 2002, 35:365-368.
• [16]Watts T, Berti I, Sapone A, Gerarduzzi T, Not T, Zielke R, Fasano A: Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats. Proc Natl Acad Sci 2005, 102:2916-2921.
• [17]Bosi E, Molteni L, Radaelli MG, Folini L, Fermo I, Bazzigaluppi E, Piemonti L, Pastore MR, Paroni R: Increased intestinal permeability precedes clinical onset of type 1 diabetes. Diabetologia 2006, 49:2824-2827.
• [18]Lee AS, Gibson DL, Zhang Y, Sham HP, Vallance BA, Dutz JP: Gut barrier disruption by an enteric bacterial pathogen accelerates insulitis in NOD mice. Diabetologia 2010, 53:741-748.
• [19]Vehik K, Dabelea D: The changing epidemiology of type 1 diabetes: why is it going through the roof? Diabetes Metab Res Rev 2011, 27:3-13.
• [20]Mathis D, Benoist C: The influence of the microbiota on type-1 diabetes: on the threshold of a leap forward in our understanding. Immunol Rev 2012, 245:239-249.
• [21]Giongo A, Gano KA, Crabb DB, Mukherjee N, Novelo LL, Casella G, Drew JC, Ilonen J, Knip M, Hyöty H, Veijola R, Simell T, Simell O, Neu J, Wasserfall CH, Schatz D, Atkinson MA, Triplett EW: Toward defining the autoimmune microbiome for type 1 diabetes. Isme J 2011, 5:82-91.
• [22]Brown CT, Davis-Richardson AG, Giongo A, Gano KA, Crabb DB, Mukherjee N, Casella G, Drew JC, Ilonen J, Knip M, Hyöty H, Veijola R, Simell T, Simell O, Neu J, Wasserfall CH, Schatz D, Atkinson MA, Triplett EW: Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS One 2011, 6:e25792.
• [23]Penders J, Thijs C, Vink C, Stelma FF, Snijders B, Kummeling I, van den Brandt PA, Stobberingh EE: Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics 2006, 118:511-521.
• [24]Musso G, Gambino R, Cassader M: Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded? Diabetes Care 2010, 3:2277-2284.
• [25]Report of the Expert Committee on the diagnosis and classification of diabetes mellitus Diabetes Care 1997, 20:1183-1197.
• [26]American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 3:S62.
• [27]Roesch LF, Casella G, Simell O, Krischer J, Wasserfall CH, Schatz D, Atkinson MA, Neu J, Triplett EW: Influence of sample storage on bacterial community diversity in fecal samples. Open Microbiol J 2009, 3:40-46.
• [28]Loham T, Roche A, Martorel R (Eds): Standardization of anthropometric measurements In The Airlie (VA) Consensus Conference. Champaign, IL: Human Kinetics; 1988:20-37.
• [29]Queipo-Ortuño MI, Boto-Ordóñez M, Murri M, Gomez-Zumaquero JM, Clemente-Postigo M, Estruch R, Cardona Diaz F, Andrés-Lacueva C, Tinahones FJ: Influence of red wine polyphenols and ethanol on the gut microbiota ecology and biochemical biomarkers. Am J Clin Nutr 2012, 95:1323-1334.
• [30]Guo X, Xia X, Tang R, Zhou J, Zhao H, Wang K: Development of a real-time PCR method for Firmicutes and Bacteroidetes in faeces and its application to quantify intestinal population of obese and lean pigs. Lett Appl Microbiol 2008, 47:367-373.
• [31]Delroisse JM, Boulvin AL, Parmentier I, Dauphin RD, Vandenbol M, Portetelle D: Quantification of Bifidobacterium spp. and Lactobacillus spp. in rat fecal samples by real-time PCR. Microbiol Res 2008, 163:663-670.
• [32]Friswell MK, Gika H, Stratford IJ, Theodoridis G, Telfer B, Wilson ID, McBain AJ: Site and strain-specific variation in gut microbiota profiles and metabolism in experimental mice. PLoS One 2010, 5:e8584.
• [33]Stach JE, Maldonado LA, Ward AC, Goodfellow M, Bull AT: New primers for the class Actinobacteria: application to marine and terrestrial environments. Environ Microbiol 2003, 5:828-841.
• [34]Matsuki T, Watanabe K, Fujimoto J, Takada T, Tanaka R: Use of 16S rRNA gene-targeted group-specific primers for real-time PCR analysis of predominant bacteria in human feces. Appl Environ Microbiol 2004, 70:7220-7228.
• [35]Bekele AZ, Koike S, Kobayashi Y: Genetic diversity and diet specificity of ruminal Prevotella revealed by 16S rRNA gene-based analysis. FEMS Microbiol Lett 2010, 305:49-57.
• [36]Rinttilä T, Kassinen A, Malinen E, Krogius L, Palva A: Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. J Appl Microbiol 2004, 97:1166-1177.
• [37]Fredricks DN, Fiedler TL, Thomas KK, Oakley BB, Marrazzo JM: Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis. J Clin Microbiol 2007, 45:3270-3276.
• [38]Lee ZMP, Bussema C, Schmidt TM: rrnDB: documenting the number of rRNA and tRNA genes in bacteria and archaea. Nucleic Acids Res 2009, 37:489-493.
• [39]Wu X, Ma C, Han L, Nawaz M, Gao F, Zhang X, Yu P, Zhao C, Li L, Zhou A, Wang J, Moore JE, Millar BC, Xu J: Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol 2010, 61:69-78.
• [40]Stuebe A: The risks of not breastfeeding for mothers and infants. Rev Obstet Gynecol 2009, 2:222-231.
• [41]Vaarala O: The gut as a regulator of early inflammation in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2011, 18:241-247.
• [42]Knip M, Virtanen SM, Becker D, Dupré J, Krischer JP, Åkerblom HK, TRIGR Study Group: Early feeding and risk of type 1 diabetes: experiences from the Trial to Reduce Insulin-dependent diabetes mellitus in the Genetically at Risk (TRIGR). Am J Clin Nutr 2011, 94:1814-1820.
• [43]Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, Gordon JI, Relman DA, Fraser-Liggett CM, Nelson KE: Metagenomic analysis of the human distal gut microbiome. Science 2006, 312:1355-1359.
• [44]Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Tims S, et al.: Enterotypes of the human gut microbiome. Nature 2011, 473:174-180.
• [45]Larsen N, Vogensen FK, van den Beg FWL, Nielsen DS, Andreasen AS, Pedersen BK, Al-Soud WA, Sørensen SJ, Hansen LH, Jakobsen M: Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 2010, 5:e9085.
• [46]Willing B, Halfvarson J, Dicksved J, Rosenquist M, Järnerot G, Engstrand L, Tysk C, Jansson JK: Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. Inflamm Bowel Dis 2009, 15:653-660.
• [47]Armougom F, Henry M, Vialettes B, Raccah D, Raoult D: Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and methanogens in anorexic patients. PLoS One 2009, 4:e7125.
• [48]Philippe D, Favre L, Foata F, Adolfsson O, Perruisseau-Carrier G, Vidal K, Reuteler G, Dayer-Schneider J, Mueller C, Blum S: Bifidobacterium lactis attenuates onset of inflammation in a murine model of colitis. World J Gastroenterol 2011, 17:459-469.
• [49]Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, Muccioli GG, Delzenne NM: Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009, 58:1091-1103.
• [50]Tzounis X, Rodriguez-Mateos A, Vulevic J, Gibson GR, Kwik-Uribe C, Spencer JP: Prebiotic evaluation of cocoa-derived flavanols in healthy humans by using a randomized, controlled, double-blind, crossover intervention study. Am J Clin Nutr 2011, 93:62-72.
• [51]Barcenilla A, Pryde SE, Martin JC, Duncan SH, Stewart CS, Henderson C, Flint HJ: Phylogenetic relationships of butyrate-producing bacteria from the human gut. Appl Environ Microbiol 2000, 6:1654-1661.
• [52]Burger-van Paassen N, Vincent A, Puiman PJ, van der Sluis M, Bouma J, Boehm G, van Goudoever JB, van Seuningen I, Renes IB: The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: implications for epithelial protection. Biochem J 2009, 420:211-219.
• [53]Lewis K, Lutgendorff F, Phan V, Soderholm JD, Sherman PM, McKay DM: Enhanced translocation of bacteria across metabolically stressed epithelia is reduced by butyrate. Inflamm Bowel Dis 2010, 16:1138-1148.
• [54]Peng LY, Li Z, Green RS, Holzman IR, Lin J: Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr 2009, 139:1619-1625.
• [55]Wright DP, Knight CG, Parker SG, Christie DL, Roberton AM: Cloning of a mucin-desulfating sulfatase gene from Prevotella strain RS2 and its expression using a Bacteroides recombinant system. J Bacteriol 2000, 182:3002-3007.
• [56]Lin HV, Frassetto A, Kowalik EJ Jr, Nawrocki AR, Lu MM, Kosinski JR, Hubert JA, Szeto D, Yao X, Forrest G, Marsh DJ: Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS One 2012, 7:e35240.
• [57]Huml M, Kobr J, Siala K, Varvařovská J, Pomahačová R, Karlíková M, Sýkora J: Gut peptide hormones and pediatric type 1 diabetes mellitus. Physiol Res 2011, 60:647-658.